Author:
Konecny Gottfried,Untch Michael,Slamon Dennis,Beryt Malgorzata,Kahlert Steffen,Felber Margret,Langer Elena,Lude Sandra,Hepp Hermann,Pegram Mark
Publisher
Springer Science and Business Media LLC
Reference45 articles.
1. Paridaens R, Biganzoli L, Bruning P, Klijn JG, Gamucci T, Houston S, Coleman R, Schachter J, Van Vreckem A, Sylvester R, Awada A, Wildiers J, Piccart M: Paclitaxel versus doxorubic in as first-line single-agent chemotherapy for metastatic breast cancer: A European organization for research and treatment of cancer randomized study with cross-over. J Clin Oncol 18: 724-733, 2000
2. Nabholtz JM, Gelmon K, Bontenbal M, Spielmann M, Catimel G, Conte P, Klaassen U, Namer M, Bonneterre J, Fumoleau P, Winograd B: Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14: 1858-1867, 1996
3. Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F, Spreafico C, Laffranchi A, Caraceni A, Martini C: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13: 2688-2699, 1995
4. Sledge GW, Neuberg D, Ingle J, Martino S, Wood W: Phase III trial of doxorubicin (A) versus paclitaxel (T) versus doxorubicin +paclitaxel (A+T) as first-line therapy for metastatic breast cancer (MBC): An intergroup trial. Proc Am Soc Clin Oncol 16: 1a, abstr 2, 1997
5. Conte PF, Gennari A, Salvadori B, Pazzagli I, Bengala C, UO Oncologia Medica: Paclitaxel plus epirubic in in advanced breast cancer. Oncology 12(1, Suppl 1): 40-44, 1998
Cited by
31 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献